Shandong Xinhua Pharmaceutical Inks Tech Transfer Deal for LXH-2201 with IMM
China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) has signed a technology transfer agreement with...
Shionogi Files NDA for S-217622 COVID-19 Antiviral Drug in China
Japan-based Shionogi & Co., Ltd has submitted a New Drug Application (NDA) to the National...
InnoCare Pharma’s ICP-490 Receives NMPA Approval for Hematological Malignancies
Beijing InnoCare Pharma (HKG: 9969) announced that it has received clinical trial approval from the...
Hrain Biotech and Novartis Receive Breakthrough Therapy Designations for CAR-T and Zolgensma
The Center for Drug Evaluation (CDE) website indicates that Hrain Biotechnology Co., Ltd’s BCMA –...
Techbank Medical Closes RMB 100M Series A to Build Global Innovation Platform
Shanghai Techbank Medical Technology Co., Ltd, a cardiovascular device maker, has reportedly closed its Series...
PackGene and Genemagic Partner on AAV Production and CDMO Services
China-based PackGene LLC has entered into a partnership with compatriot firm Genemagic Biosciences Co., Ltd....
PersonGen BioTherapeutics’ TAA06 Receives Clinical Trial Approval for B7-H3 CAR-T Therapy
The Center for Drug Evaluation (CDE) website indicates that PersonGen BioTherapeutics (Suzhou) Co., Ltd’s TAA06,...
Akeso Biopharma’s Cadonilimab Achieves National Delivery in China
China-based biotech Akeso Biopharma (HKG: 9926) announced the national delivery of its cadonilimab (AK104), marking...
Sobi’s Anakinra (Kineret) Prioritized for Review in China for FMF Treatment
The Center for Drug Evaluation (CDE) website indicates that Swedish Orphan Biovitrum AB’s (Sobi; BMV:...
Arctic Vision Enrolls First Patient in ARVN003 Phase III Trial for Presbyopia
China-based ophthalmic therapies developer Arctic Vision announced the first patient enrollment in a Phase III...
Guangdong Releases 2022 Non-Immunization Vaccine Catalog (7th Batch)
The Guangdong Provincial Center for Disease Control and Prevention and Guangdong Medicine Exchange jointly released...
WuXi Biologics’ MFG14 Facility Approved for Microbial Product Manufacturing
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its...
JW Therapeutics Initiates Phase I Study of JWATM204 for Hepatocellular Carcinoma
China-based JW Therapeutics (HKG: 2126) announced the initiation of a Phase I clinical study for...
GenScript Biotech’s ProBio Subsidiary Receives USD 37.25M Investment from Zhenjiang Gaoxin
Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that Zhenjiang Gaoxin...
Zhiyi Bio Raises RMB 100M in Series B++ Round for LBP Pipeline Development
China-based leading live biotherapeutics (LBP) company Guangzhou Zhiyi Biotechnology Co., Ltd has recently raised RMB...
Brii Biosciences Exercises Option for VIR-3434 in Greater China
China-based Brii Biosciences Limited (HKG: 2137) announced the exercise of its option to acquire exclusive...
Innovent Biologics Doses First Patient in IBI112 Phase II Study for Ulcerative Colitis
China-based Innovent Biologics, Inc. (HKG: 1801) announced the successful first patient dosing in a Phase...
VivaVision Biotech and Dragon Sail Pharmaceutical Partner on Ophthalmology R & D
China’s VivaVision Biotech Inc. has entered into a partnership with compatriot firm Dragon Sail Pharmaceutical....
Junshi Biosciences Receives FDA Approval for PI3K-α Inhibitor RP903 in Breast Cancer Study
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) announced that it has received approval from the...
InnoCare Pharma’s Guangzhou Plant Approved for Orelabrutinib Commercial Production
Beijing InnoCare Pharma (HKG: 9969) announced that as of June 30, its manufacturing plant in...